Title: Clinical Holds in Early Oncology Drug Development

Authors: Alexandra Snyder\* MD, Dinesh De Alwis, PhD, Asthika Goonewardene, Priti S.

Hegde\* PhD

\*Co-corresponding

Affiliation and contacts

AS: Two River, Inc. 689 Fifth Ave, New York, NY 10022

AG: Truist Securities. 711 Fifth Ave, New York, NY 10022

DD: Early Oncology Development, Merck & Co., Inc., Rahway, NJ, USA

PSH: Foundation Medicine. 150 Second Street, Cambridge, MA 02141

## Abstract

Clinical holds in oncology are necessary to safeguard patients. Researchers are alerted to holds by news sources, but a systematic evaluation of clinical holds in early oncology drug development is lacking. Analysis of publicly disclosed clinical holds in oncology from 2016-2021 identified 39 holds. The majority (n=29) were for toxicity-related reasons, with fewer for chemistry, manufacturing and controls (CMC) (n=7) or other reasons (n=3). Toxicity-related holds took a median of 74 days till resolution, whereas chemistry, manufacturing and controls (CMC)-related holds took a median of 108 days to resolve. Acknowledging the limited sample size and scope of stock market conditions, toxicity-related clinical holds impacted the market value of small/medium sized biotechs by a median of -15%, which is far more than large biopharma (median 0%). These data suggest that toxicity-related clinical holds are common in early oncology and can have a more detrimental impact on small/medium sized biotech sponsors, the latter of which could have substantial financial repercussions, particularly in "biotech bear markets" where public investing in the sector has fallen out of favor (as in 2021-2022).

## Text:

Development of novel oncology drugs and platforms now occurs primarily in the context of smaller biotechnology companies. In the years 2020-21, 36% of oncology drug approvals by the US FDA were of drugs developed by a biotech company and 64% by big pharma (Supplementary Table S1). Importantly, a large majority of approvals for big pharma constituted label expansions, whereas 100% of approvals for small biotech were related to novel therapies or platforms<sup>1</sup>. Indeed, approximately 80% of the overall industry pipeline comes from emerging biopharma companies<sup>2</sup>. Of the 112 oncology drug approvals in 2020-2021, 40 were of drugs developed by small biotechs. Of these 40, based on company disclosures, 9 were put on partial or full clinical hold at some point in their development. Such holds have at times led to a dramatic drop in public interest in a biotech, despite evidence of efficacy (Fig. 1A).

Chimeric antigen receptor (CAR) therapies provide an example of platform development that has benefited from time spent in understanding clinical safety, including revisions caused by clinical holds. CARs outfit T cells and other immune cell types with receptors that can attack cancer and have now become standard of care for the treatment of some patients with lymphoma and multiple myeloma. However, their development path has featured pauses and redirections, as these drugs can lead to substantial systemic inflammation, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). A study of a CD19 CAR-T therapy, JCAR015, was put on hold in 2016 due to 3 patient deaths out of 20 accrued patients. Initially, fludarabine, a drug used to condition the body prior to the experimental therapy, was faulted. However, after an additional 2 patients died, the trial was put on hold indefinitely and the sponsor, Juno, shifted development to JCAR017, an optimized CAR-T drug that also targeted CD19 but with different viral vector, binding domain, costimulatory domain and T-cell selection process. Juno lost \$1.36B in market cap when they announced the first clinical hold in July 2016, and \$1.39B when they announced the second hold in November 2016 (Supplementary Fig. S1), although it bears noting that other fluctuations occurred in the stock price outside of these events. The optimized agent, JCAR017, was ultimately approved by the FDA for treatment of lymphomas<sup>3</sup>; this success, among other variables, has spawned vigorous development and optimization in the cell therapy space.

To identify larger trends in the field, as there is no repository of clinical holds in early oncology, we surveyed press releases and public investor call transcripts with the words "clinical hold" available on Bloomberg from 2016 to 2021 for US-based companies (Table 1). 39 oncology-

related holds occurred during this period. Of these, among the 29 toxicity-related holds, 10 were for cell therapies, 6 for T-cell engagers (TCE), 5 for antibodies in immuno-oncology, 4 for antibody-drug conjugates and 4 for small molecules. 18 were resolved, 6 were terminated and 5 were ongoing as of this writing. Seven holds were for reasons related to chemistry, manufacturing and controls (CMC): 3 for cell therapies, 1 for TCE and 3 for IO, all of which were resolved. Three holds were for other reasons. Toxicity-related holds took a median of 74 days till resolution irrespective of the platform (with immuno-oncology (IO) agents an outlier at 100 days median) (Table 1B), whereas CMC-related holds took a median of 108 days to resolve.

Acknowledging the limited sample size, clinical holds impacted the market value of small/medium sized biotechs more than large biopharma (Table 1C). The rebound after hold removal was greater for CMC- related holds than safety-related holds (Fig. 1B). We hypothesize that this contrast may be because, despite hold resolution, toxicities become part of the risk:benefit profile of the agent, impacting the drug profile beyond the hold.

Some limitations of our methodology include:

- We were only able to capture clinical holds that were publicly disclosed in a press release
  or on an investor call; a clinical hold may not be material enough for a large biopharma
  company to issue a press release, so we may be undercounting clinical holds experienced
  by larger companies.
- We were only able to capture companies that continued to exist; therefore, our survey likely underestimates the impact of clinical holds on the fate of biotech companies.
- Our analysis of share price reactions accounts for the absolute change in share price, but does not account for the relative movement versus the broader stock market or relevant indices, nor does it account for investor sentiment that is already baked into the share price. Our analysis of events was restricted to 2016-2021, and this represents a period of more favorable market conditions for biotech investing. In more recent times (2021-to date), biotech has been in a "bear market" where long term public market investing has fallen out of favor. In these conditions, negative share price movements due to clinical holds can be exacerbated.

Technological breakthroughs paired with ongoing clinical need make oncology a fertile space for drug development. Such development is attended by myriad risks, including to the safety of patients treated on clinical trials, and requires the consistent production of high quality drug products. Clinical holds are a necessary part of drug development intended to protect

patient safety. Historical examples (described in an upcoming publication by Snyder et al.<sup>4</sup>) demonstrate that careful optimization of oncology drugs can lead to the development of therapies that improve and prolong lives; Project Optimus, an FDA initiative start in 2022 to improve dose-finding in oncology, underscores the need for methodical early drug development. While qualitative in nature, data described here suggest that clinical holds, whether for toxicity or CMC, do not necessarily hinder likelihood of eventual drug approval, and may result in better therapeutics. However, such events can cause a significant drop in investor interest, particularly for small biotechnology companies. While such fluctuations are a natural part of drug development, this analysis suggests that a careful examination of each case may be instructive, informing the field whether actions taken as a result of the hold may in fact lead to an approval-worthy drug profile.

## References

- 1. Oncology (Cancer)/Hematologic Malignancies Approval Notification. (2022).
- 2. Investment in Biopharma is Reaching an Inflection Point. (2021).
- 3. Abramson, J.S., *et al.* Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. *Lancet* **396**, 839-852 (2020).
- 4. Snyder, A. Balancing Speed, Science and Regulatory Requirements in Oncology Drug Development. Under review, (2022).

## Disclosures:

AS is an employee of Two River, Inc and owns shares in Allogene Therapeutics and Merck & Co., Inc., Rahway, NJ, USA.

PSH is an employee of Foundation Medicine, Inc and owns shares in Roche, Bolt Therapeutics and TCR2.

DD is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and owns shares in Merck & Co., Inc., Rahway, NJ, USA.

Figures and Tables Associated with Clinical Holds in Early Oncology Drug Development Authors: Alexandra Snyder MD, Dinesh De Alwis, PhD, Asthika Goonewardene, Priti Hegde PhD




Figure 1A. Share Price Reaction to Clinical Hold Announcement - SMID Biotech

This chart represents the share price movement on the day of or day after a clinical hold was first reported, against the prior 3 day rolling average. The X axis indicates the company and the date the hold was announced. Dark purple bars represent share price reactions for clinical holds due to toxicity, light purple bars represent clinical holds due to CMC issues, and gray bars represent clinical holds due to other reasons (PK/PD, trial disclosures, etc.). Dotted lines represent median share price reaction to clinical holds due to toxicity (dark purple) or CMC (light purple). In this chart, only SMID- cap biotech companies' share price reactions and medians are represented. SMID=small and medium cap biotechs, here defined as value less than \$10B. Large cap defined as value greater than or equal to \$10 billion.




Figure 1B. Share Price Reaction to Clinical Hold Resolution - SMID Biotech

This chart represents the share price movement on the day of or day after a clinical hold was reported as successfully resolved, against the prior 3 day rolling average. The X axis indicates the company and the date the resolution was announced. Dark purple bars represent share price reactions for clinical holds due to toxicity, light purple bars represent clinical holds due to CMC issues, and gray bars represent clinical holds due to other reasons (PK/PD, trial disclosures, etc.). Dotted lines represent median share price reaction to resolving clinical holds due to toxicity (dark purple) or CMC (light purple). In this chart, only SMID-cap biotech companies' share price reactions and medians are represented.

Table 1A. Mechanisms and outcomes of clinical holds in oncology, 2016-2021. CMC = chemistry, manufacturing and controls.


Breakdown	Of The Clinical	Holds Consid	ered						
			Mech	anism of A	ction			Outcome	
	Total		Imm Engagers						
		Cell Tx	& Other bsAbs	IO	Conj	Small Mol	Resolved	Terminated	Ongoing
Toxicity	29	10	6	5	4	4	18	6	5
CMC	7	3	1	3	0	0	7	0	0
Other	3						2		1
Total	39						27	6	6

Table 1B. Median time to resolution of clinical holds, 2016-2021.

Time To Resolve Clinical Holds (Days)			
Reason for Hold: Toxicity or Patient Death 74			
Cell Therapy	71		
Immune Engagers & Other Bispecific Antibodies	69		
Immuno-Oncology	100		
Conjugates	65		
Reason for Hold: CMC	108		
Cell Therapy	98		

Table 1C. Median share price moves relative to hold announcement, 2016-2021.

Median Share Price Moves (On Announcement vs Prior 3 Day Average)				
Clinical Hold Announced	All companies	SMID-cap	Large-cap	
Reason for Hold: Toxicity or Patient Death	-11%	-15%	0%	
Reason for Hold: CMC	-6%	-6%		
Clinical Hold Successfully Resolved				
Reason for Hold: Toxicity or Patient Death	-1%	-1%	-1%	
Reason for Hold: CMC	4%	4%		
Clinical Hold Leads To Asset Termination				
Reason for Hold: Toxicity or Patient Death	-8%	-8%		



Supplementary Tab Approval	le S1. Oncology Approvals by the US FDA, 2020-2021  Description	Date
	On December 15, 2021, the Food and Drug Administration approved abatacept (Orencia, Bristol-Myers Squibb Company) for the prophylaxis of acute graft versus host disease (aGVHD),	
FDA approves abatacept for	in combination with a calcineurin inhibitor (CNI) and methotrexate (MTX), in adults and pediatric patients 2 years of	
prophylaxis of acute graft versus	age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched	
host disease	unrelated donor.	12/15/2021
FDA approves pembrolizumab for	On December 3,2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) for	
of Stage IIB or IIC	the adjuvant treatment of adult and pediatric (≥12 years of age) patients with stage IIB or IIC melanoma following complete	10/0/000
melanoma	resection.  On December 2, 2021, the Food and Drug Administration approved rituximab (Rituxan, Genentech, Inc.) in combination	12/3/2021
FDA approves rituximab plus chemotherapy for	with chemotherapy for pediatric patients (≥6 months to <18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL),	
pediatric cancer indications	Burkitt-like lymphoma (BLL), or mature B-cell acute leukemia (B-AL).	12/2/2021
FDA approves Darzalex Faspro, Kyprolis,	On November 30, 2021, the Food and Drug Administration approved daratumumab + hyaluronidase- fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib	
and Dexamethasone for	(Kyprolis, Amgen, Inc.) plus dexamethasone foradult patients with relapsed or refractory multiple myeloma who have	
Multiple Myeloma	received 1 to 3 prior lines of therapy.	12/01/2021
	On November 29, 2021, the Food and Drug Administration approved pafolacianine (Cytalux, On Target Laboratories, LLC), an optical imaging agent, for adult patients with ovarian cancer	
FDA approves pafolacianine for identifying	as an adjunct for interoperative identification of malignant lesions. Pafolacianine is a fluorescent drug that targets folate receptor which may be overexpressed in ovarian cancer. It is	
malignant ovarian cancer lesions FDA approves	used with a Near-Infrared (NIR) fluorescence imaging system cleared by the FDA for specific use with pafolacianine.	11/29/2021
sirolimus protein-	On November 22, 2021, the Food and Drug	
bound particles for malignant perivascular	Administration approved sirolimus protein-bound particles for injectable suspension (albumin-bound) (Fyarro, Aadi Bioscience, Inc.) for adult patients with locally advanced unresectable or	
epithelioid cell	metastatic malignant perivascular epithelioid cell tumor	44 /22 /222

11/23/2021

(PEComa).

tumor

On November 17, 2021, the Food and Drug FDA approves Administration approved pembrolizumab (Keytruda, Merck & pembrolizumab for Co., Inc., Rahway, NJ, USA) for the adjuvant treatment of adjuvant treatment patients with renal cell carcinoma (RCC) at intermediate-high or of renal cell high risk of recurrence carcinoma following nephrectomy, or following nephrectomy and resection 11/17/2021 of metastatic lesions. On October 29, 2021, the Food and Drug Administration granted FDA approves accelerated approval to asciminib (Scemblix, Novartis AG) for asciminib for patients with Philadelphia chromosome-positive chronic Philadelphia myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs), and chromosomepositive chronic approved asciminib for adult patients with Ph+ CML in CP with myeloid leukemia the T315I mutation. 10/29/2021 On October 15, 2021, the Food and Drug Administration FDA approves approved atezolizumab (Tecentrig, Genentech, Inc.) for adjuvant atezolizumab as treatment following resection and platinum-based adjuvant treatment chemotherapy in patients with stage II to IIIA non-small cell lung for non-small cell cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. lung cancer 10/15/2021 On October 13, 2021, the Food and Drug Administration FDA approves approved pembrolizumab (Keytruda, Merck & Co., Inc., pembrolizumab combination for Rahway, NJ, USA) in combination with chemotherapy, with or the first-line without bevacizumab, for patients with persistent, recurrent or treatment of metastatic cervical cancer whose tumors express PD-L1 (CPS cervical cancer ≥1), as determined by an FDA- approved test. 10/13/2021 On October 12, 2021, the Food and Drug Administration approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor FDA approves (HR)-positive, human epidermal growth factor receptor 2 (HER2)abemaciclib with negative, node-positive, early breast cancer at high risk of endocrine therapy recurrence and a Ki-67 score ≥20%, as determined by an FDA for early breast approved test. This is the first CDK 4/6 inhibitor approved for adjuvant treatment of breast cancer. 10/12/2021 cancer FDA approves brexucabtagene autoleucel for relapsed or refractory B-cell On October 1, 2021, the Food and Drug Administration precursor acute approved brexucabtagene autoleucel (Tecartus, Kite Pharma, lymphoblastic Inc.) for adult patients with relapsed or refractory B-cell leukemia precursor acute lymphoblastic leukemia (ALL). 10/1/2021 On September 22, 2021, the Food and Drug Administration FDA approves approved ruxolitinib (Jakafi, Incyte Corp.) for chronic graft-

versus-host disease (cGVHD) after failure of one or two lines of

9/22/2021

chronic graft-versus systemic therapy in adult and pediatric patients 12 years and

ruxolitinib for

host disease

older.

	On September 20, 2021, the Food and Drug Administration granted accelerated approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor conjugate, for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.  On September 17, 2021, the Food and Drug Administration approved cabozantinib (Cabometyx, Exelixis, Inc.) for adult and	9/20/2021
FDA approves cabozantinib for differentiated thyroid cancer FDA grants accelerated	pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer (DTC) that has progressed following prior VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.	9/17/2021
approval to mobocertinib for metastatic non- small cell lung cancer with EGFR exon 20 insertion mutations FDA grants	Food and Drug Administration granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.	9/15/2021
accelerated approval to zanubrutinib for marginal zone lymphoma	Food and Drug Administration granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.	9/14/2021
FDA approves zanubrutinib for Waldenström's macroglobulinemia FDA approves ivosidenib for	Food and Drug Administration approved zanubrutinib (Brukinsa, BeiGene) for adult patients with Waldenström's macroglobulinemia (WM).	9/1/2021
advanced or metastatic cholangiocarcinom a	Food and Drug Administration approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) for adult patients with previously treated, locally advanced or metastatic cholangiocarcinoma with an isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.	8/25/2021
FDA approves nivolumab for adjuvant treatment of urothelial carcinoma	Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Co.) for the adjuvant treatment of patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection.	8/19/2021

FDA grants accelerated approval to dostarlimab-gxly for dMMR advanced solid tumors	Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.	8/18/2021
FDA approves belzutifan for cancers associated with von Hippel- Lindau disease	Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc., Rahway, NJ, USA), a hypoxia-inducible factor inhibitor for adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery	8/13/2021
FDA approves lenvatinib plus pembrolizumab for advanced renal cell carcinoma FDA approves	Food and Drug Administration approved the combination of lenvatinib (Lenvima, Eisai) plus pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) for first-line treatment of adult patients with advanced renal cell carcinoma (RCC).	8/10/2021
pembrolizumab for high-risk early- stage triple- negative breast cancer FDA grants regular	Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. Food and Drug Administration approved pembrolizumab	7/26/2021
approval to pembrolizumab and lenvatinib for advanced endometrial carcinoma	(Keytruda, Merck & Co., Inc., Rahway, NJ, USA) in combination with lenvatinib (Lenvima, Eisai) for patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation.	7/21/2021
FDA approves belumosudil for chronic graft-versus host disease	Food and Drug Administration approved belumosudil (Rezurock, Kadmon Pharmaceuticals, LLC), a kinase inhibitor, for adult and pediatric patients 12 years and older with chronic graft-versushost disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.	7/16/2021
and	Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least one prior line of therapy including lenalidomide and a proteasome	

multiple myeloma inhibitor.

7/9/2021

FDA grants regular approval to enfortumab vedotin-ejfv for locally advanced or metastatic urothelial cancer	Food and Drug Administration approved enfortumab vedotinejfv (Padcev, Astellas Pharma US, Inc.), a Nectin-4-directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand (PD-L1) inhibitor and platinum-containing chemotherapy, or are ineligible for cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.	7/9/2021
FDA approves asparaginase erwinia chrysanthemi (recombinant) for leukemia and lymphoma	Food and Drug Administration approved asparaginase erwinia chrysanthemi (recombinant)-rywn) (Rylaze, Jazz Pharmaceuticals, Inc.) as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase	7/1/2021
FDA approves avapritinib for advanced systemic mastocytosis FDA grants	Food and Drug Administration approved avapritinib (Ayvakit™, Blueprint Medicines Corp.) for adult patients with advanced systemic mastocytosis (AdvSM), including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).	6/16/2021
accelerated approval to infigratinib for metastatic cholangiocarcinom a	Food and Drug Administration granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics, Inc.), a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test	5/28/2021
FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC FDA grants	Food and Drug Administration granted accelerated approval to sotorasib (Lumakras™, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.	5/28/2021
accelerated approval to amivantamab- vmjw for metastatic non- small cell lung cancer	FDA granted accelerated approval to amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.	5/21/2021

FDA approves nivolumab for resected esophageal or GEJ cancer	Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) for patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy.	5/20/2021
FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer	Food and Drug Administration granted accelerated approval to pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.	5/5/2021
FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma	On April 23, 2021, the Food and Drug Administration granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta, ADC Therapeutics SA), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.	4/23/2021
FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer FDA approves nivolumab in combination with	Food and Drug Administration granted accelerated approval to dostarlimab-gxly (Jemperli, GlaxoSmithKline LLC) for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior platinum-containing regimen.	4/22/2021
chemotherapy for metastatic gastric cancer and esophageal adenocarcinoma FDA grants accelerated approval to sacituzumab govitecan for	Food and Drug Administration approved nivolumab (Opdivo, Bristol-Myers Squibb Company) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.	4/16/2021
_	FDA grants accelerated approval to sacituzumab govitecan for advanced urothelial cancer.	4/13/2021

FDA grants regular approval to sacituzumab govitecan for triplenegative breast cancer	Food and Drug Administration granted regular approval to sacituzumab govitecan (Trodelvy, Immunomedics Inc.) for patients with unresectable locally advanced or metastatic triplenegative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease.	4/7/2021
FDA approves new dosing regimen for cetuximab	Food and Drug Administration approved a new dosage regimen of 500 mg/m2 as a 120-minute intravenous infusion every two weeks (Q2W) for cetuximab (Erbitux, ImClone LLC) for patients with K-Ras wild-type, EGFR-expressing colorectal cancer (mCRC) or squamous cell carcinoma of the head and neck (SCCHN). Food and Drug Administration approved isatuximab-irfc (Sarclisa, sanofi-aventis U.S. LLC) in combination with carfilzomib and dexamethasone, for the treatment of adult	4/6/2021
FDA approves isatuximab-irfc for multiple myeloma	patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. March 31, 2021	3/31/2021
FDA approves idecabtagene vicleucel for multiple myeloma	Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma. March 26, 2021 Food and Drug Administration approved pembrolizumab (Keytruda, Merck & Co., Inc., Rahway, NJ, USA) in combination with platinum and fluoropyrimidine-based chemotherapy for	3/26/2021
FDA approves pembrolizumab for esophageal or GEJ carcinoma FDA approves	patients with metastatic or locally advanced esophageal or gastroesophageal (GEJ) (tumors with epicenter 1 to 5 centimeters above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation. March 22, 2021.	3/22/2021
tivozanib for relapsed or refractory advanced renal cell carcinoma	Food and Drug Administration approved tivozanib (Fotivda, AVEO Pharmaceuticals, Inc.), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. March 10, 2021	3/10/2021

FDA grants accelerated approval to axicabtagene ciloleucel for Food and Drug Administration granted accelerated approval to relapsed or axicabtagene ciloleucel (Yescarta, Kite Pharma, Inc.) for adult refractory follicular patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. lymphoma 3/5/2021 Food and Drug Administration granted regular approval to FDA approves Iorlatinib (Lorbrena, Pfizer Inc.) for patients with metastatic non-Iorlatinib for small cell lung cancer (NSCLC) whose tumors are anaplastic metastatic ALKlymphoma kinase (ALK)-positive, detected by an FDA-approved positive NSCLC 3/3/2021 test. March 3, 2021 Food and Drug Administration granted accelerated approval to melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory FDA grants agent, and one CD-38 directed monoclonal antibody. Efficacy accelerated was evaluated in HORIZON (NCT02963493), a multicenter, singleapproval to arm trial. Eligible patients were required to have relapsed melphalan refractory multiple myeloma. Patients received melphalan flufenamide for flufenamide 40 mg intravenously on day 1 and dexamethasone relapsed or 40 mg orally (20 mg for patients ≥75 years of age) on day 1, 8, refractory multiple 15 and 22 of each 28-day cycle until disease progression or myeloma unacceptable toxicity. 2/26/2021 Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) for the first-line FDA approves treatment of patients with advanced non-small cell lung cancer cemiplimab-rwlc (NSCLC) (locally advanced who are not candidates for surgical for non-small cell resection or definitive chemoradiation or metastatic) whose lung cancer with tumors have high PD-L1 expression (Tumor Proportion Score [TPS] > 50%) as determined by an FDA-approved test, with no high PD-L1 expression EGFR, ALK or ROS1 aberrations. 2/22/2021 FDA approves cemiplimab-rwlc for locally advanced and Food and Drug Administration approved cemiplimab-rwlc for metastatic basal cell carcinoma locally advanced and metastatic basal cell carcinoma. 2/9/2021

FDA approves lisocabtagene maraleucel for relapsed or refractory large B- cell lymphoma	Food and Drug Administration approved lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B. February 5, 2021	2/5/2021
	Food and Drug Administration granted accelerated approval to umbralisib (Ukoniq, TG Therapeutics), a kinase inhibitor including PI3K-delta and casein kinase CK1-epsilon, for the following indications: Adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen; Adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.	2/5/2021
FDA grants accelerated approval to tepotinib for metastatic non- small cell lung cancer	Food and Drug Administration granted accelerated approval to tepotinib (Tepmetko, EMD Serono Inc.) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.	2/3/2021
FDA approves nivolumab plus cabozantinib for advanced renal cell carcinoma FDA grants accelerated	Food and Drug Administration approved the combination of nivolumab (Opdivo, Bristol-Myers Squibb Co.) and cabozantinib (Cabometyx, Exelixis) as first-line treatment for patients with advanced renal cell carcinoma (RCC).	1/22/2021
approval to Darzalex Faspro for newly diagnosed light chain amyloidosis FDA approves fam-	Food and Drug Administration granted accelerated approval to daratumumab plus hyaluronidase (Darzalex Faspro, Janssen Biotech Inc.) in combination with bortezomib, cyclophosphamide and dexamethasone for newly diagnosed light chain (AL) amyloidosis.	1/15/2021
trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas	Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.	1/15/2021

FDA approves crizotinib for		
children and young adults with relapsed or refractory, systemic anaplastic large cell	Food and Drug Administration approved crizotinib (Xalkori, Pfizer Inc.) for pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. The safety and efficacy of crizotinib have not been established in older adults	
lymphoma FDA approves osimertinib as adjuvant therapy for non-small cell lung cancer with	with relapsed or refractory, systemic ALK-positive ALCL. Food and Drug Administration approved osimertinib (TAGRISSO, AstraZeneca Pharmaceuticals LP) for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as	1/14/2021
EGFR mutations FDA approves relugolix for advanced prostate	detected by an FDA-approved test. Food and Drug Administration approved the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix, (ORGOVYX, Myovant Sciences, Inc.) for adult patients	12/18/2020
cancer FDA approves	with advanced prostate cancer.	12/18/2020
selinexor for refractory or relapsed multiple myeloma	Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Food and Drug Administration approved margetuximab-cmkb	12/18/2020
FDA approves margetuximab for metastatic HER2- positive breast	(MARGENZA, MacroGenics) in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.	
cancer		12/16/2020
FDA approves pralsetinib for RET-altered thyroid	Food and Drug Administration approved pralsetinib (GAVRETO, Blueprint Medicines Corporation) for adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy or RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-	
cancers	refractory (if radioactive iodine is appropriate).  Food and Drug Administration granted accelerated approval to	12/1/2020
FDA grants accelerated approval to naxitamab for high- risk neuroblastoma	naxitamab (DANYELZA, Y-mAbs Therapeutics, Inc.) in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a	
in bone or bone marrow	partial response, minor response, or stable disease to prior therapy.	11/25/2020

FDA grants accelerated approval to pembrolizumab for locally recurrent unresectable or metastatic triple negative breast	Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triplenegative breast cancer (TNBC) whose tumors express PD-L1	44 (40 (000
FDA grants regular approval to venetoclax in	(CPS ≥10) as determined by an FDA approved test.	11/13/2020
combination for untreated acute myeloid leukemia	Food and Drug Administration grants regular approval to venetoclax in combination for untreated acute myeloid leukemia.  Food and Drug Administration extended the approval of	10/16/2020
FDA extends approval of pembrolizumab for classical Hodgkin lymphoma FDA approves	pembrolizumab (KEYTRUDA®, Merck & Co., Inc., Rahway, NJ, USA) for the following indications: adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) and pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy.	10/14/2020
nivolumab and ipilimumab for unresectable malignant pleural mesothelioma	Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for adult patients with unresectable malignant pleural mesothelioma.	10/2/2020
FDA approves pralsetinib for lung cancer with RET gene fusions	Food and Drug Administration granted accelerated approval to pralsetinib (GAVRETO, Blueprint Medicines Corporation) for adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. Food and Drug Administration approved azacitidine tablets (ONUREG, Celgene Corporation) for continued treatment of	9/4/2020
FDA approves Onureg (azacitidine tablets) for acute myeloid leukemia	patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.	9/1/2020
	On August 20, 2020, the Food and Drug Administration approved carfilzomib (KYPROLIS, Onyx Pharmaceuticals, Inc.) and daratumumab (DARZALEX, Janssen Biotech, Inc.) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received one	
multiple myeloma	to three lines of therapy.	8/20/2020

FDA granted		
accelerated	Food and Drug Administration approved belantamab mafodotin-	
approval to	blmf (Blenrep, GlaxoSmithKline) for adult patients with relapsed	
belantamab	or refractory multiple myeloma who have received at least 4	
mafodotin-blmf for	prior therapies, including an anti-CD38 monoclonal antibody, a	
multiple myeloma	proteasome inhibitor, and an immunomodulatory agent.	8/5/2020
	FDA granted accelerated approval to tafasitamab-cxix	
FDA grants	(MONJUVI, MorphoSys US Inc.), a CD19-directed cytolytic	
accelerated	antibody, indicated in combination with lenalidomide for adult	
approval to	patients with relapsed or refractory diffuse large B-cell	
tafasitamab-cxix for	lymphoma (DLBCL) not otherwise specified, including DLBCL	
diffuse large B-cell	arising from low grade lymphoma, and who are not eligible for	
lymphoma	autologous stem cell transplant.	7/31/2020
FDA approves		
atezolizumab for		
BRAF V600	Food and Drug Administration approved atezolizumab	
unresectable or	(Tecentriq, Genentech, Inc.) in combination with cobimetinib	
metastatic	and vemurafenib for patients with BRAF V600 mutation-positive	
melanoma	unresectable or metastatic melanoma.	7/30/2020
FDA approves		
brexucabtagene	Food and Drug Administration granted accelerated approval to	
autoleucel for	brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company),	
relapsed or	a CD19-directed genetically modified autologous T cell	
refractory mantle	immunotherapy, for the treatment of adult patients with	
cell lymphoma	relapsed or refractory mantle cell lymphoma (MCL).	7/24/2020
FDA approves oral		
combination of		
decitabine and	Food and Drug Administration approved an oral combination of	
cedazuridine for	decitabine and cedazuridine (INQOVI, Astex Pharmaceuticals,	
myelodysplastic	Inc.) for adult patients with myelodysplastic syndromes (MDS)	
syndromes	including the following:	7/7/2020
FDA approves		
avelumab for	Food and Drug Administration approved avelumab (BAVENCIO,	
urothelial	EMD Serono, Inc.) for maintenance treatment of patients with	
carcinoma	locally advanced or metastatic urothelial carcinoma (UC) that	
maintenance	has not progressed with first-line platinum-containing	
treatment	chemotherapy.	6/30/2020
FDA approves	Food and Drug Administration approved pembrolizumab	
pembrolizumab for	(KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) for the first-	
first-line treatment	line treatment of patients with unresectable or metastatic	
of MSI-H/dMMR	microsatellite instability-high (MSI-H) or mismatch repair	
colorectal cancer	deficient (dMMR) colorectal cancer. June 29, 2020	6/29/2020

FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer FDA approves	Food and Drug Administration approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase–zzxf (PHESGO, Genentech, Inc.) for subcutaneous injection	6/29/2020
pembrolizumab for cutaneous squamous cell carcinoma	Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) for patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation	6/24/2020
FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma	Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.	6/22/2020
FDA granted accelerated approval to tazemetostat for follicular lymphoma	Food and Drug Administration granted accelerated approval to tazemetostat (TAZVERIK, Epizyme, Inc.), an EZH2 inhibitor, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) for the treatment of adult and pediatric patients with	6/18/2020
FDA approves pembrolizumab for adults and children with TMB-H solid tumors	unresectable or metastatic tumor mutational burden-high (TMB H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.	6/16/2020
FDA approves gemtuzumab ozogamicin for CD33-positive AML in pediatric patients FDA grants	Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARG, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older.	6/16/2020
accelerated approval to lurbinectedin for metastatic small	Food and Drug Administration granted accelerated approval to lurbinectedin(ZEPZELCA, Pharma Mar S.A.) for adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. June 15, 2020	C /45 /2020

6/15/2020

2020

cell lung cancer

6/10/2020 5/29/2020
5/29/2020
5/26/2020
5/22/2020
5/19/2020
5/18/2020

FDA approves	Food and Drug Administration approved ripretinib (QINLOCK,
ripretinib for	Deciphera Pharmaceuticals, LLC.), for adult patients with
advanced	advanced gastrointestinal stromal tumor (GIST) who have
gastrointestinal	received prior treatment with 3 or more kinase inhibitors,
stromal tumor	including imatinib.

FDA grants	FDA	grants
------------	-----	--------

accelerated Food and Drug Administration granted accelerated approval to approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with rucaparib for BRCA- deleterious BRCA mutation (germline and/or somatic)mutated metastatic associated metastatic castration-resistant prostate cancer castration-resistant (mCRPC) who have been treated with androgen receptorprostate cancer

directed therapy and a taxane-based chemotherapy. 5/15/2020

5/15/2020

Food and Drug Administration approved the combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co.) plus ipilimumab FDA approves nivolumab plus (YERVOY, Bristol-Myers Squibb Co.) as first-line treatment for ipilimumab for first-patients with metastatic non-small cell lung cancer whose line mNSCLC (PD-L1 tumors express PD-L1(≥1%), as determined by an FDA-approved tumor expression test, with no epidermal growth factor receptor (EGFR) or

≥1%) anaplastic lymphoma kinase (ALK) genomic tumor aberrations. 5/15/2020

Food and Drug Administration expanded the indication of FDA grants accelerated pomalidomide (POMALYST, Celgene Corporation) to include treating adult patients with AIDS-related Kaposi sarcoma after approval to pomalidomide for failure of highly active antiretroviral therapy and Kaposi sarcoma

Kaposi sarcoma in adult patients who are HIV-negative. 5/14/2020

Food and Drug Administration expanded the indication of olaparib (LYNPARZA®, AstraZeneca Pharmaceuticals, LP) to FDA approves include its combination with bevacizumab for first-line olaparib plus maintenance treatment of adult patients with advanced bevacizumab as epithelial ovarian, fallopian tube, or primary peritoneal cancer maintenance who are in complete or partial response to first-line platinumtreatment for based chemotherapy and whose cancer is associated with ovarian, fallopian homologous recombination deficiency positive status defined by tube, or primary either a deleterious or suspected deleterious BRCA mutation,

peritoneal cancers and/or genomic instability. 5/8/2020

FDA approves selpercatinib for lung and thyroid cancers with RET	Food and Drug Administration granted accelerated approval to selpercatinib (RETEVMO, Eli Lilly and Company) for the following indications: Adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC); Adult and pediatric patients ≥12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy; Adult and pediatric patients ≥12 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if	
gene mutations or fusions FDA grants accelerated	radioactive iodine is appropriate).	5/8/2020
approval to capmatinib for metastatic non- small cell lung	Food and Drug Administration granted accelerated approval to capmatinib (TABRECTA, Novartis) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition	
cancer	(MET) exon 14 skipping as detected by an FDA-approved test.	5/6/2020
FDA approves daratumumab and hyaluronidase-fihj for multiple	Food and Drug Administration approved daratumumab and hyaluronidase-fihj (DARZALEX FASPRO, Janssen Biotech, Inc.) for adult patients with newly diagnosed or relapsed/refractory multiple myeloma. This new product allows for subcutaneous	
myeloma	dosing of daratumumab. May 1, 2020	5/1/2020
FDA approves niraparib for first-line maintenance of advanced ovarian	Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial	
cancer	response to first-line platinum-based chemotherapy.  Food and Drug Administration granted accelerated approval to a new dosing regimen of 400 mg every six weeks for	4/29/2020
FDA approves new dosing regimen for pembrolizumab	pembrolizumab (KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) across all currently approved adult indications, in addition to the current 200 mg	4/28/2020
FDA grants accelerated approval to	every three weeks dosing regimen.	
sacituzumab govitecan-hziy for metastatic triple	Food and Drug Administration granted accelerated approval to sacituzumab govitecan-hziy (TRODELVY, Immunomedics, Inc.) for adult patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic	
negative breast cancer	disease.	4/22/2020

FDA approves ibrutinib plus rituximab for chronic lymphocytic leukemia FDA grants accelerated	Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).	4/21/2020
approval to pemigatinib for cholangiocarcinom a with an FGFR2 rearrangement or fusion	Food and Drug Administration granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.  Food and Drug Administration approved tucatinib (TUKYSA,	4/20/2020
FDA approves tucatinib for patients with HER2- positive metastatic breast cancer FDA approves	Seattle Genetics, Inc.) in combination with trastuzumab and capecitabine, for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting.	4/17/2020
mitomycin for low- grade upper tract urothelial cancer FDA approves selumetinib for neurofibromatosis	Food and Drug Administration approved mitomycin (JELMYTO™, UroGen Pharma) for adult patients with low-grade upper tract urothelial cancer (LG-UTUC).	4/15/2020
type 1 with symptomatic, inoperable plexiform neurofibromas FDA approves encorafenib in combination with	Food and Drug Administration approved selumetinib (KOSELUGO, AstraZeneca) for pediatric patients, 2 years of age and older, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).	4/10/2020
cetuximab for metastatic colorectal cancer with a BRAF V600E mutation	Food and Drug Administration approved encorafenib (BRAFTOVI, Array BioPharma Inc.) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, detected by an FDA-approved test, after prior therapy.	4/8/2020

Food and Drug Administration approved luspatercept-aamt (REBLOZYL, Celgene Corporation) for the treatment of anen failing an erythropoiesis stimulating agent and requiring 2 comore red blood cell (RBC) units over 8 weeks in adult patient with very low- to intermediate-risk myelodysplastic syndrom	r its
luspatercept-aamt with ring sideroblasts (MDS-RS) or with	
for anemia in myelodysplastic/myeloproliferative neoplasm with ring	. /2 /2 22 2
adults with MDS sideroblasts and thrombocytosis (MDS/MPN-RS-T).	4/3/2020
FDA approves durvalumab for Food and Drug Administration approved durvalumab (IMFIN	171
extensive-stage AstraZeneca) in combination with etoposide and either	,
small cell lung carboplatin or cisplatin as first-line treatment of patients wi	th
cancer extensive-stage small cell lung cancer (ES-SCLC).	3/30/2020
FDA grants	
accelerated	
approval to	14-
nivolumab and Food and Drug Administration granted accelerated approva ipilimumab the combination of nivolumab and ipilimumab (OPDIVO and	
combination for YERVOY, Bristol-Myers Squibb Co.) for patients with	ı
hepatocellular hepatocellular carcinoma (HCC) who have been previously	
carcinoma treated with sorafenib.	3/10/2020
Food and Drug Administration approved isatuximab-irfc	
(SARCLISA, sanofi-aventis U.S. LLC) in combination with	
FDA approves pomalidomide and dexamethasone for adult patients with	
FDA approves pomalidomide and dexamethasone for adult patients with isatuximab-irfc for multiple myeloma who have received at least two prior	r 2/2/2020
FDA approves pomalidomide and dexamethasone for adult patients with isatuximab-irfc for multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitory.	
FDA approves pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor FDA approves Food and Drug Administration approved neratinib (NERLYN)	ζ,
FDA approves pomalidomide and dexamethasone for adult patients with isatuximab-irfc for multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitory.	ζ, e for
FDA approves pomalidomide and dexamethasone for adult patients with isatuximab-irfc for multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibito FDA approves Food and Drug Administration approved neratinib (NERLYN) neratinib for Puma Biotechnology, Inc.) in combination with capecitabine	K, e for reast
FDA approves pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor FDA approves Food and Drug Administration approved neratinib (NERLYNX neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive by	K, e for reast
FDA approves isatuximab-irfc for multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibito FDA approves neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 base regimens in the metastatic setting.  Food and Drug Administration granted accelerated approval.	k, e for reast ed 2/25/2020 I to
pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor FDA approves neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 base regimens in the metastatic setting.  FOOd and Drug Administration granted accelerated approva tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and pedia	k, e for reast ed 2/25/2020 I to
pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor FDA approves neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 base regimens in the metastatic setting.  FOA approves tazemetostat for patients aged 16 years and older with metastatic or locally	k, e for reast ed 2/25/2020 I to
pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor FDA approves neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 base cancer regimens in the metastatic setting.  FOOd and Drug Administration granted accelerated approvatazemetostat for patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete	K, e for reast ed 2/25/2020 I to tric
pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor FDA approves neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 base regimens in the metastatic setting.  FOA approves tazemetostat for patients aged 16 years and older with metastatic or locally	k, e for reast ed 2/25/2020 I to
pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor FDA approves neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 base cancer regimens in the metastatic setting.  FOOd and Drug Administration granted accelerated approvatazemetostat for patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete	(, e for reast ed 2/25/2020 I to tric 1/23/2020
pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor FOA approves neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 base regimens in the metastatic setting.  FOOd and Drug Administration granted accelerated approva tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and pediate patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.	2/25/2020 I to tric 1/23/2020
pomalidomide and dexamethasone for adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor Fod and Drug Administration approved neratinib (NERLYN) neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 base regimens in the metastatic setting.  Fod and Drug Administration granted accelerated approva tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and pediate patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.  FDA approves  Food and Drug Administration approved avapritinib (AYVAK avapritinib for gastrointestinal metastatic gastrointestinal stromal tumor (GIST) harboring	2/25/2020 I to tric  1/23/2020 IIT, ole or
pomalidomide and dexamethasone for adult patients with isatuximab-irfc for multiple myeloma therapies including lenalidomide and a proteasome inhibitor FDA approves Food and Drug Administration approved neratinib (NERLYNX) neratinib for Puma Biotechnology, Inc.) in combination with capecitabine adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 base regimens in the metastatic setting.  Food and Drug Administration granted accelerated approva tazemetostat (TAZVERIK, Epizyme, Inc.) for adults and pedia patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.  FDA approves  Food and Drug Administration approved avapritinib (AYVAK avapritinib for Blueprint Medicines Corporation) for adults with unresectal	2/25/2020 I to tric  1/23/2020 IIT, ole or

FDA approves
pembrolizumab for
KEYTRUDA, Merck & Co., Inc., Rahway, NJ, USA) for the
BCG-unresponsive,
high-risk nonmuscle invasive
bladder cancer
(NMIBC) with carcinoma in situ (CIS) with or without papillary
tumors who are ineligible for or have elected not to undergo

1/8/2020

cystectomy.